Discovery of potent LRRK2 inhibitors by ensemble virtual screening strategy and bioactivity evaluation

Abstract

Leucine-rich repeat kinase 2 (LRRK2) has been reported to be associated with familial and idiopathic Parkinson's disease (PD) risk and is a promising target for drug discovery against PD. To identify novel and effective LRRK2 inhibitors, an ensemble virtual screening strategy by combining fingerprint similarity, complex-based pharmacophore and structure-based molecular docking was proposed and applied. Using this strategy, we finally selected 25 compounds from ∼1.7 million compounds for in vitro and in vivo tests. Firstly, the kinase inhibitory activity tests of compounds based on ADP-Glo assay identified three most potent compounds LY2023-19, LY2023-24 and LY2023-25 with IC₅₀ of 556.4 nM, 218.1 nM and 22.4 nM for LRRK2 G2019S mutant, respectively. The further cellular experiments also indicated that three hit compounds significantly inhibited Ser935 phosphorylation of both wide-type and G2019S LRRK2 with IC₅₀ ranging from 27 nM to 1674 nM in HEK293T cells. The MD simulations of three compounds and G2019S LRRK2 showed the hydrogen bond formed by Glu1948 and Ala1950 is crucial for the binding of LRRK2. Afterwards, 6-OHDA-induced PD zebrafish model was constructed to evaluate the neuroprotective effects of hit compounds. The locomotion of the 6-OHDA treated zebrafish larvae was improved after treatment with LY2023-24. The obtained results can provide valuable guidance for the development of PD drugs by targeting LRRK2.